Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon for postprandial hypoglycaemia after Roux-en-Y gastric bypass
2020-005241-16Phase 2Completed
- Sponsor
- Center for Diabetes Research
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dasiglucagon in Postprandial hyperinsulinemic hypoglycemia (PHH) and postprandial hypoglycemia (2 arms), sponsored by Center for Diabetes Research. Primary endpoint: Percentage of time in hypoglycaemia. Started Feb 2021; status: completed.
02
Drugs
dasiglucagon
03
Conditions
Postprandial hyperinsulinemic hypoglycemia (PHH)postprandial hypoglycemia
Beyond the preview
Go deeper on 2020-005241-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005241-16.